

---

**From:** cogno@cogno.org.au  
**Sent:** Monday, 6 November 2023 2:37 PM  
**Subject:** COGNO LUMOS2 now officially open in Australia  
**Attachments:** LUMOS2\_CommsForCOGNO\_v1.0\_20231103 final.pdf

Dear COGNO member,

COGNO is excited to announce that the LUMOS2 trial in relapsed grade 2 and/or 3 IDH-mutant glioma has now officially opened in Australia! In further good news, the first participant has been enrolled in September 2023 at the Peter MacCallum Cancer Centre, Melbourne. This participant's tumour has been successfully profiled and also reviewed by the trial's Molecular Tumour Advisory Panel, with the participant now assigned to an interventional arm provided within the LUMOS2 trial. A second trial site, St Vincent's Hospital NSW, has also been activated this week.

In achieving this important milestone, we wish to acknowledge the exceptional leadership of Trial Chair Professor Hui Gan, Medical Oncologist from the ONJCRI. We thank all collaborating partners, in particular Professor David Thomas and the team at Omico, for providing access to their expertise and support in molecular profiling for study participants.

We would like to commend and thank the very significant efforts of the team from the NHMRC Clinical Trials Centre, the trial sponsor University of Sydney, site investigators and trial coordination teams as well as the Australian Trial Management Committee in successfully bringing this trial to Australian patients.

We also wish to acknowledge the Medical Research Future Fund (MRFF) and Australian Brain Cancer Mission (ABCM) for their support of the trial, as well as the industry partners including Akesobio Australia, Antengene, Kazia Therapeutics and Aucentra Therapeutics. In addition, Canadian sites will also be supported by FORUS Therapeutics with funding provided by the Canadian Cancer Society and Brain Canada, with trial oversight by the Canadian Cancer Trials Group (CCTG).

Further information regarding the study can be found in the attached information and via <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384830&isReview=true>

We would strongly encourage referral of any potential participants to relevant sites when activated. Any study queries can be sent to [LUMOS2.study@sydney.edu.au](mailto:LUMOS2.study@sydney.edu.au).

COGNO looks forward to progressing activation of the LUMOS2 study across all remaining Australian study sites as well as internationally with our colleagues at the Canadian Cancer Trials Group (CCTG).

Associate Professor Eng-Siew Koh  
MBBS FRANZCR

Chair, Cooperative Trials Group for Neuro-Oncology (COGNO)

e: [cogno@cogno.org.au](mailto:cogno@cogno.org.au) | w: [www.cogno.org.au](http://www.cogno.org.au)



## LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided Therapies

Protocol No: CTC 0378, COGNO 22/01

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384830&isReview=true>

The LUMOS2 study **officially opened in Australia** on 31 August 2023.

The precision oncology umbrella study hypothesizes that patients with relapsed G2/3 IDH-mutant gliomas will benefit most from treatment with agents based on their molecular profile, either with a targeted agent where an actionable target is found or alternatively with other interventional agents being tested for these tumours. This is a joint partnership between COGNO and Omico, which is led by Professor David Thomas.

The LUMOS2 study currently has 3 available treatment arms, recruiting 19 patients per arm, with two other arms currently in development. Funding has also been secured to expand the study to multiple sites in Canada, with the first site currently scheduled for activation in 2024.

For more study details, please contact **Study Chair Professor Hui Gan** at [LUMOS2.study@sydney.edu.au](mailto:LUMOS2.study@sydney.edu.au).

	Site	State	Principal Investigator	Activation Date
1	Peter MacCallum Cancer Centre	VIC	Dr Jim Whittle	31 Aug 2023
2	St Vincent's Hospital, Sydney	NSW	A/Prof Hao-Wen Sim	3 Nov 2023
3	Monash Medical Centre - Clayton	VIC	Dr Elizabeth Ahern	
4	Austin Hospital	VIC	Prof Hui Gan	
5	St Vincent's Hospital Melbourne	VIC	A/Prof Tony Dowling	
6	Liverpool Hospital	NSW	Dr Adam Cooper	
7	Royal North Shore Hospital	NSW	A/Prof Helen Wheeler	
8	Calvary Mater Newcastle	NSW	Dr James Lynam	
9	Royal Hobart Hospital	TAS	Prof Rosemary Harrup	
10	Flinders Medical Centre	SA	Dr Ganessan Kichenadasse	
11	Royal Brisbane and Women's Hospital	QLD	A/Prof Zarnie Lwin	
12	Sir Charles Gairdner Hospital	WA	Dr Brandon Lau	